Advertisement

Adult Immunization

 
How to Handle Medical Misinformation in the Clinic
February 03, 2023

These tips from a family physician on managing misinformation in the exam room can help reduce the spread of false and misleading narratives.

The COVID-19 Vaccine Halo Effect: Survey Highlights
January 26, 2023

The Kaiser Family Foundation survey found a 10% drop in the proportion of adults who say MMR vaccination should be required for school attendance, and other "halo" effects.

CDC Releases First Estimates of Bivalent mRNA COVID-19 Booster Effectiveness against XBB/XBB.1.5
January 25, 2023

Preliminary estimates showed relative bivalent booster dose vaccine effectiveness against XBB/XBB.1.5 for at least the first 3 months after vaccination.

Moderna Reports Adult RSV Vaccine Efficacy of 84% in Phase 3 ConquerRSV Trial
January 18, 2023

The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.

Long COVID After Mild Infection: Most Symptoms Resolve After 1 Year, Finds Large Israeli Study
January 17, 2023

Overall dyspnea was the most common symptom of long COVID in the first year after infection, according to the nationwide retrospective cohort study.

CDC Real-world Studies Show Bivalent Boosters Protect Against Severe COVID-19 Disease
December 16, 2022

One study showed the boosters provide significant protection against hospitalization and ED care and the other found vaccine effectiveness of 84% in older adults.

COVID-19 Vaccines Have Saved 3 Million Lives in the 2 Years Since the First EUA
December 13, 2022

The vaccination campaign in the US also has prevented more than 18 million hospitalizations and saved $1 trillion in medical costs, according to a modeling study.

FDA Grants Priority Review to Pfizer’s RSV Vaccine Candidate for Older Americans
December 08, 2022

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.

Vaccine Confidence Significantly Eroded During Pandemic, Across Demographics
November 10, 2022

Confidence in vaccines is lower post-pandemic across all demographic groups and is not limited to traditional "anti-vaxxers," say authors of a new study.

RSV Older Adult Vaccine Candidate from GSK Wins FDA Priority Review, PDUFA Date Set
November 02, 2022

The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.

Advertisement
Advertisement